Dr. Trevor Campbell, MD, CCFP
Dr. Trevor Campbell, MD, CCFP
Episode 32: What Aspiring Healthcare Leaders Must Know About Value Assessments with Sarah K. Emond, President and CEO of ICER (the Institute for Clinical and Economic Review)
Episode 32: What Aspiring Healthcare Leaders Must Know About Value Assessments with Sarah K. Emond, President and CEO of ICER (the Institute for Clinical and Economic Review)
Episode 32: What Aspiring Healthcare Leaders Must Know About Value Assessments with Sarah K. Emond, President and CEO of ICER (the Institute for Clinical and Economic Review)
Monday 20th May 2024
Join Pam Divack and Sarah Emond as they discuss the role of value assessments in healthcare and ICER's impact on pricing and access.
31 minutes
Informative
Educational
Encouraging
Hopeful
Engaging
About this podcast
Author:
Dr. Trevor Campbell, MD, CCFP
Overview:
Categories:
Holistic Health Innovations
Mindfulness & Technology in Health
Mindful Recovery
Healing from Sexual Trauma
Innovative Treatments & Recovery Paths
Links:
Visit site
Episodes:
99 (View all)
Do you want to link to this podcast?
Get the buttons here!Healthcare Value Assessments: Insights from ICER's CEO
Episode Overview
- Understanding value assessments is crucial for sustainable healthcare.
- ICER provides data for price negotiation and policy-making.
- Challenges include pricing gene therapies and large population drugs.
- Incorporating patient perspectives improves clinical trials.
- Aspiring leaders should focus on innovation and collaboration.
If we don't figure out how to pay for these in a sustainable way, we're not going to have that next wave of innovation coming.
In this engaging episode of Healthscape, Pam Divack chats with Sarah K. Emond, the President and CEO of ICER, to explore the importance of value assessments in healthcare. ICER, an independent non-profit research organisation, is known for evaluating the clinical and economic value of prescription drugs and medical innovations. The conversation dives into the history and evolution of ICER, highlighting its collaboration with various stakeholders in the healthcare ecosystem.
You'll learn about the increasing need for value assessments and comparative effectiveness research due to industry pressures and trends. Sarah sheds light on how ICER aims to improve the US healthcare system by providing crucial data that aids in price negotiation and policy-making. She discusses the challenges posed by new therapies, such as cell and gene treatments, and the implications of pricing drugs for large populations like obesity treatments.
Sarah also emphasises the importance of incorporating patient perspectives into clinical trials and value assessments. This episode offers valuable insights for aspiring healthcare leaders, especially those navigating the complexities of pricing and access in a rapidly evolving industry. Whether you're an MBA student or a seasoned healthcare professional, understanding these dynamics is essential for driving innovation and ensuring sustainable access to treatments. Tune in to discover how you can contribute to a more equitable healthcare system.